Navigation Links
Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
Date:12/5/2012

ns, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, without limitation, statements regarding the anticipated benefits from the appointment of Mr. Mir as CFO, and the likelihood that it will lead to successful capital raising efforts; the development and implementation of a sustainable fiscal road map that can increase shareholder value by supporting continued growth, particularly in the marketing and sales area; our belief that our 2012 commercialization plan was integral to the record sales in the third quarter; that stakeholders in PBI will understand how fortunate they are that Mr. Mir has joined PBI as CFO; and that PCT is a powerful, enabling, and game-changing technology platform.  These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: possible difficulties or delays in the implementation of the Company's strategies that may adversely affect the Company's continued commercialization of its PCT-based product line; changes in customer's needs and technological innovations; the Company's sales force may not be successful in selling the Company's product lines because scientists may not perceive the advantages of these products over other sample preparation methods; and if actual operating costs are higher than anticipated, or revenues from product sales are less than anticipated, the Company may need additional capital sooner than anticipated. Further, given the uncertainty in the capital markets and the current status of the Company's product development and commercialization activities, there can be no assurance that the Company will secure the
'/>"/>
SOURCE Pressure BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pressure BioSciences, Inc. Continues Global Sales Reach Expansion with Distribution Agreements for China, Vietnam, Laos, Cambodia, Australia, and New Zealand
2. Pressure BioSciences, Inc. Reaches Agreement with Investors on Initial $600,000 Tranche of $1.2 Million Above-Market Private Placement; Proceeds to Support Continued Commercialization of PCT Product Platform
3. Regado Biosciences, Inc. to Present at Needham & Companys 11th Annual Healthcare Conference in New York, NY
4. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
5. Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA
6. Lakewood-Amedex Inc. Appoints Marie E. Knight To Its Board Of Directors
7. Amarantus Appoints Super Bowl Champion Toi Cook to Board of Advisors to Advance TBI Program
8. Regulus Appoints Victor Knopov, Ph.D. as Vice President, Pharmaceutical Development
9. CTI Appoints Monique Greer, Senior Vice President, Corporate Communications and Investor Relations
10. Novel Cancer Immune Therapy Developer Oncos Therapeutics Appoints Experienced Industry Leader Frans Wuite as President and CEO
11. Sanguine Appoints Darlene Rosario, Vice President of Regulatory Affairs & Quality at Biothera, Inc., to Clinical Advisory Board and Ethics Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... -- MEI Pharma, Inc. (Nasdaq: MEIP ), an oncology ... cancer, announced today that Daniel P. Gold , Ph.D., ... NewsMakers in the Biotech Industry conference on Friday, September ... Broadway Hotel & Conference Center in New York ... accessed at www.meipharma.com . A replay will be available ...
(Date:9/18/2014)... 18 septembre 2014 Mapi, société créée ... 1974, a été depuis 40 ans l,un ... cliniques traditionnelles par des évaluations recentrées sur ... les impacts économiques des traitements. ... A cours d,une récente conférence téléphonique ...
(Date:9/18/2014)... SeqLL Inc., the owner of ... today the closing of a $1M Series-A funding ... Diagnostic Technologies, will increase the power of tSMS™ ... in March 2013 by Daniel Jones, a former ... BioSciences, SeqLL has continued to offer Helicos’ sequencing ...
(Date:9/18/2014)... sweeteners, promoted as aids to weight loss and diabetes ... and metabolic disease; and they do it in a ... the gut microbiota the substantial population of bacteria ... experiments in mice and humans, were published today in ... Elinav of the Weizmann Institute,s Immunology Department, who led ...
Breaking Biology Technology:MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 31974 - 2014 - Mapi fête ses 40 ans 2SeqLL Closes Series-A Funding Round for Expansion of Single Molecule Sequencing 2Gut bacteria, artificial sweeteners and glucose intolerance 2Gut bacteria, artificial sweeteners and glucose intolerance 3
... Sweden, July 14 PharmaSurgics AB.,successfully completes Phase ... is safe and well tolerated. Initially developed to ... combines,the pharmacological effect of PXL01 with the physical ... to be the first anti-adhesion drug on the,market. ...
... LA JOLLA, Calif., July 14 Synthetic Genomics ... solutions to address a variety of global challenges including ... and development agreement with ExxonMobil Research and Engineering Company ... algae. , , ...
... , ... today announced clearance for marketing by the United States Food and Drug Administration (K083292) ... , ... 14, 2009 -- EMcision Ltd. today announced clearance for marketing by the United States ...
Cached Biology Technology:Novel Product for the Prevention of Post-Surgical Adhesion Formation Completes Phase I Clinical Study 2Synthetic Genomics Inc. and ExxonMobil Research and Engineering Company Sign Exclusive, Multi-Year Agreement to Develop Next Generation Biofuels Using Photosynthetic Algae 2Synthetic Genomics Inc. and ExxonMobil Research and Engineering Company Sign Exclusive, Multi-Year Agreement to Develop Next Generation Biofuels Using Photosynthetic Algae 3EMcision Announces 510(k) Clearance of the Habib EndoHPB, its Novel Bipolar RF Device for the Palliation of Biliary and Pancreatic Tumours 2
(Date:9/17/2014)... four-year project, delivering its first release in 2004. After ... several EC projects, as a part of the EC-FP7 ... to increase the general awareness of the work done ... of the Fauna Europaea results, the Biodiversity ... tools to prepare data papers for all 56 major ...
(Date:9/17/2014)... developed, very cleverly, some lessons on how to create ... Joseph Shaw, director of the Optical Technology Center at ... at the nanoscale, we,ll discover them." , Some of ... during a conference called "The Nature of Light: Light ... the University of Arizona College of Optical Sciences. The ...
(Date:9/17/2014)... New research from the Copenhagen Centre for Social Evolution ... evolutionary theory that birth weight and -length can partially ... disorders such as autism and schizophrenia later in life. ... births, and subsequent hospital diagnoses for up to 30 ... factors. The study is published today in the ...
Breaking Biology News(10 mins):Contributions on Fauna Europaea: Data papers as innovative model on expert involvement 2Nature's designs inspire research into new light-based technologies 2Nature's designs inspire research into new light-based technologies 3Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3
... -- Traditionally addressed through hand-weeding and/or herbicide application, controlling ... production. Increased labor costs have made hand-weeding prohibitive as ... may be effective and less expensive, non-target herbicide loss ... the environment. To address the economic and environmental impact ...
... -- Associate Professor Paul Blowers of the University of ... 2011 Arizona Professor of the Year, recognized for commitment ... Advancement of Teaching and the Council for Advancement and ... announced the award on Nov. 17 in Washington, D.C. ...
... CAMBRIDGE, Mass. -- Significant progress has been ... psychiatric disease. Recent studies have identified common genetic ... significant risk. One example of a rare cause ... (DISC1) gene, first identified in a large Scottish ...
Cached Biology News:Biodegradable mulches successfully control weeds in container-grown arborvitae 2Arizona Engineering associate professor earns national recognition 2Picower: Schizophrenia gene associated with psychiatric disorders and brain development 2Picower: Schizophrenia gene associated with psychiatric disorders and brain development 3
... The MEGAscript RNAi Kit is ... large mass amounts of ready-to-use ... non-mammalian systems. The MEGAscript RNAi ... patented high-yield transcription technol-ogy and ...
UGT1A6 (D-20)...
... With its patented technology, the Lone Wolf ... any Normally Open proportional valve available on ... operation, provides repeatable high-speed performance, and ensures ... , Enhances system control and patient ...
Normal Hamster Serum...
Biology Products: